Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination
ATLANTA, GA, July 24, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a strategic shift in its Gedeptin® clinical development program, with a new emphasis on evaluating Gedeptin as a neoadjuvant therapy in combination with pembrolizumab for patients with primary, resectable head and neck squamous cell carcinoma (HNSCC).
The revised strategy follows the landmark results of the KEYNOTE-689 Phase 3 trial, published in the New England Journal of Medicine on June 18, 2025, which demonstrated a significant improvement in event-free survival (EFS) with the addition of perioperative pembrolizumab in resectable, locally advanced HNSCC patients. These data represent the first validated use of PD-1 inhibition in curative-intent HNSCC and have catalyzed a major shift in treatment paradigms toward neoadjuvant immunotherapy.
GeoVax’s new Phase 2 trial (AdPNP-203) will evaluate the addition of intra-tumoral Gedeptin®, intravenous fludarabine, and pembrolizumab in patients eligible for curative surgery. The trial is designed to assess major pathological response (MPR) and associated immunologic and biomarker outcomes following two pre-surgical cycles of therapy as well as event-free survival over a one-year period. Gedeptin’s tumor-targeting, immune-sensitizing mechanism may help overcome the limitations of checkpoint monotherapy by enhancing immune activation within the tumor microenvironment. Trial initiation is planned for 2026.
“The KEYNOTE-689 results support our view that neoadjuvant checkpoint inhibition can transform the treatment of head and neck cancer,” said Dr. Kelly McKee, Chief Medical Officer at GeoVax. “By integrating Gedeptin into this emerging standard, we hope to improve both local tumor clearance and event-free survival, especially for high-risk or PD-L1-low patients.”
“This is a strategic shift in our program,” added David Dodd, Chairman and CEO of GeoVax. “We believe Gedeptin’s localized cytotoxic mechanism, when combined with systemic checkpoint inhibition for first-line treatment, can meaningfully improve therapeutic outcomes in patients with resectable HNSCC.”
Rationale for Combination Strategy
As highlighted in the NEJM editorial, the benefit in KEYNOTE-689 may be driven primarily by the neoadjuvant component of immunotherapy. However, many patients still experience local or distant relapse, underscoring the need for intensified strategies in the perioperative window. Gedeptin, with its dual cytotoxic and immune-priming mechanism, may serve as an ideal partner to checkpoint inhibitors by converting “cold” tumors into “hot” immunogenic targets.
About Gedeptin®
Gedeptin is a gene-directed enzyme prodrug therapy (GDEPT) using a non-replicating adenoviral vector encoding purine nucleoside phosphorylase (PNP). Once delivered directly into tumors and followed by fludarabine, PNP enzymatically converts the prodrug into a cytotoxic compound, selectively targeting tumor cells while sparing healthy tissue. This localized approach aims to reduce toxicity, enhance immune visibility, and enable immune checkpoint synergy.
Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers and is backed by a robust intellectual property portfolio. GeoVax’s ongoing innovation in immune-sensitizing therapies supports a broader strategy to complement checkpoint inhibitors and overcome tumor immune resistance across solid tumor types.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
OLC was well-tolerated and enabled serum phosphate control in over 90% of patients with a low pill burden
LOS ALTOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the publication of pivotal trial data describing the safety and tolerability of oxylanthanum carbonate (OLC) in chronic kidney disease (CKD) patients on dialysis in the Clinical Journal of the American Society of Nephrology.
The publication, entitled “A Phase 2 Clinical Trial of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia,” examines the safety and tolerability of OLC at clinically effective doses with a goal serum phosphate concentration of ≤5.5 mg/dL. Eighty-six patients were treated with OLC in this open-label single arm Phase 2 study. At screening, only 59% of patients had serum phosphate levels of ≤5.5 mg/dL (phosphate control). OLC was well tolerated and enabled serum phosphate control in >90% of patients with a low pill burden (two-thirds of patients receiving three or fewer tablets/day). Pharmacokinetic analysis showed that systemic absorption of OLC (measured as lanthanum) was minimal to none in CKD patients.
“With the favorable tolerability, strong efficacy and low pill burden highlighted in this prestigious publication, we continue to believe that OLC has the potential to offer patients a new option that could help improve adherence to treatment over time,” said Shalabh Gupta, MD, Chief Executive Officer of Unicycive. “This pivotal study was the final clinical evidence needed for our NDA package. We continue to collaborate closely with the U.S. Food and Drug Administration as we address their outstanding manufacturing questions and align on a path forward to bring OLC to this underserved patient population as quickly as possible.”
Key Findings:
More than 90% of patients with hyperphosphatemia taking OLC achieved effective phosphate control.
Two-thirds of patients required three or fewer OLC tablets per day to achieve target serum phosphate levels, with most requiring no more than one tablet with each meal.
OLC was well tolerated in CKD patients on dialysis. The most common treatment-related adverse events were gastrointestinal (9% diarrhea; 6% vomiting) and only 4% of patients discontinued treatment due to treatment-related adverse events.
“Despite the various treatment options available, there remains a significant need in managing hyperphosphatemia, which heavily impacts people with chronic kidney disease on dialysis,” said Dr. Pablo Pergola, MD, PhD, Research Director, Clinical Advancement Center, Renal Associates, P.A., and principal investigator of the trial. “These data add to the growing body of clinical evidence supporting the potential of OLC as an innovative treatment option, demonstrating effective phosphate control and reducing pill burden. OLC’s unique profile offers a promising alternative with favorable tolerability, potentially transforming the standard of care for patients.”
About Oxylanthanum Carbonate (OLC) OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden.
Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. The NDA submission package is based on data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, and the chemistry, manufacturing and controls (CMC) data. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.
About Hyperphosphatemia Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.1 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.
1Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145. Epub 2023 Jun 29. PMID: 37229723; PMCID: PMC10371371.
About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted Orphan Drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Forward-looking statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
TROY, Mich., July 24, 2025 (GLOBE NEWSWIRE) — Kelly, a leading global specialty talent solutions provider, will release its second-quarter earnings before the market opens on Thursday, August 7, 2025. In conjunction with its earnings release, Kelly will publish a financial presentation and host a live webcast of a conference call with financial analysts at 9 a.m. ET on August 7 to review the results from the quarter and answer questions.
The presentation and a link to the live webcast will be accessible through the Company’s public website on the Investor Relations page under Events & Presentations. The webcast will be recorded, and a replay will be available within one hour of completion of the event through the same link as the live webcast.
About Kelly
Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect more than 400,000 people with work every year. Our suite of outsourcing and consulting services ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2024 was $4.3 billion. Learn more at kellyservices.com.
Key Points: – AEye’s Apollo lidar is now fully integrated into NVIDIA’s DRIVE AGX platform. – The partnership gives AEye access to top global automakers and positions it as a key supplier in autonomous driving. – Apollo’s software-defined architecture and long-range sensing provide a scalable edge for smart mobility applications.
Shares of AEye, Inc. (Nasdaq: LIDR) surged Thursday after the company announced a major milestone: its flagship Apollo lidar sensor is now fully integrated into NVIDIA’s DRIVE AGX platform, a central hub in the autonomous driving world. This integration isn’t just a technical step — it’s a commercial launchpad that could put AEye’s technology inside millions of vehicles over the next decade.
NVIDIA’s DRIVE ecosystem is used by top-tier automakers globally, from early autonomous pioneers to traditional OEMs embracing next-gen driver assistance. By becoming an official component of the DRIVE AGX suite, AEye now has direct access to these automakers — positioning it as a go-to lidar provider in the race toward self-driving adoption.
AEye’s Apollo sensor, part of the company’s 4Sight™ Flex lidar family, offers a unique mix of long-range detection (up to 1 km), compact design, and software-defined capabilities. That last point may be the most compelling: Apollo’s software-defined nature means the sensor can receive over-the-air updates, just like a smartphone, enabling continuous improvement without physical replacement.
“This is how vehicles are being built today — smarter, more connected, and designed to evolve,” said CEO Matt Fisch. “Being certified on NVIDIA DRIVE AGX validates our approach and puts us on a direct path to global scale.”
AEye’s technology isn’t just another lidar unit. Apollo is designed to integrate seamlessly into modern vehicle architecture, including behind the windshield — a feat many competitors struggle with due to limitations in wavelength and range. By using 1550 nm wavelength lidar, Apollo combines safety-critical resolution with the ability to remain aesthetically unobtrusive, a growing demand among automakers.
Beyond the automotive world, AEye teased broader ambitions. The company plans to unveil OPTIS, a full-stack physical AI solution aimed at transportation, infrastructure, and security markets. This suggests that AEye is thinking bigger — positioning itself as not just a lidar company, but as a smart sensing platform ready to power everything from autonomous delivery vehicles to smart cities.
For small- and micro-cap investors, AEye’s NVIDIA milestone offers a compelling glimpse of what success looks like in the sensor space: strategic partnerships, scalable architecture, and technology that fits into how mobility is evolving. With software-defined sensing quickly becoming the industry standard, Apollo’s adoption through NVIDIA could be the early signal of significant commercial momentum.
In a market where many lidar startups have stumbled, AEye’s continued focus on performance, integration, and flexibility is starting to separate it from the pack — and now, with NVIDIA in its corner, its road ahead may be wide open.
Travelzoo® provides its 30 million members with exclusive offers and one-of-a-kind experiences personally reviewed by our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. We work in partnership with more than 5,000 top travel suppliers—our long-standing relationships give Travelzoo members access to irresistible deals.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Mixed second quarter results. Revenues significantly increased 13.1% to $23.9 million, a sequential quarterly increase from 5.3% in Q1, reflecting its strategic shift toward a subscription based model. Adj. EBITDA fell short of our expectations, however, due to a step up in customer acquisition spend and the purchase of “distressed” vouchers.
Favorable customer acquisition dynamics. Customer acquisition costs went up in Q2 to $38 from $28 in Q1, but still remains positive. Total return is $58, $40 from the annual subscription fee and $18 from transactions. Management anticipates to continue to aggressively spend on customer acquisition in light of the favorable Return on Investment. These moves support a longer term attractive revenue outlook, but have a near term adverse impact on adj. EBITDA.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Increasing longer-term rail car delivery estimates. While we have maintained our rail car delivery estimates for 2025 through 2027, we have increased our delivery estimates for 2028 through 2030. We now forecast rail car deliveries of 5,500, 5,750, and 6,000, respectively, compared with our prior estimates of 5,000, 5,000, and 5,000. While we had previously assumed that RAIL would operate four production lines with an aggregate capacity of 5,000 rail cars through 2030, we now assume the company will operate five production lines with a total capacity of 6,250 rail cars beginning in 2028. Our prior assumption had been that the company could begin producing a new line of higher-margin tank cars using existing capacity at the expense of lower margin products. Because we think tank cars could add an incremental 500 or more orders beginning in 2028, the tank cars would be incremental to existing orders with five production lines.
Updating earnings estimates. We forecast 2025 EBITDA and EPS of $45.9 million and $0.47, respectively, while our 2026 estimates are $48.6 million and $0.53. While our 2025 and 2026 EBITDA estimates are unchanged, we have increased our forward estimates, which may be found in the financial model at the end of this report. While our earnings estimates have increased, gross margin as a percentage of sales remains unchanged at 13.0%, 13.3%, 13.5%, and 13.8% in 2027, 2028, 2029, and 2030, respectively, while selling, general, and administrative expense as a percentage of sales increased modestly.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Seanergy Maritime Holdings Corp. is a prominent pure-play Capesize shipping company listed in the U.S. capital markets. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. The Company’s operating fleet consists of 18 vessels (1 Newcastlemax and 17 Capesize) with an average age of approximately 13.4 years and an aggregate cargo carrying capacity of approximately 3,236,212 dwt. Upon completion of the delivery of the previously announced Capesize vessel acquisition, the Company’s operating fleet will consist of 19 vessels (1 Newcastlemax and 18 Capesize) with an aggregate cargo carrying capacity of approximately 3,417,608 dwt. The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Second Quarter 2025 Estimate Revisions. We are raising our Q2 2025 net revenue forecast to $36.5 million from $35.9 million, driven by stronger-than-expected time charter equivalent (TCE) rates. However, we are lowering our adjusted EBITDA and EPS estimates to $16.7 million and $0.11, respectively, from $17.3 million and $0.17, reflecting higher operating expenses of $29.1 million versus $27.5 million previously. The increase reflects a full quarter of the expanded fleet as well as higher-than-expected dry-docking activity.
Full-Year 2025 Estimate Changes. We are increasing our 2025 revenue forecast to $143.4 million from $142.9 million, as we expect improving rate momentum to continue through year-end. We are also raising our operating expense estimate to $113.9 million from $109.4 million, reflecting a greater number of anticipated dry-docking days. As a result, we are lowering our adjusted EBITDA projection to $67.7 million from $70.5 million and our EPS estimate to $0.51 from $0.74.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Updating second quarter estimates. We are raising our second quarter revenue and adjusted earnings per share estimates to $56.7 million and $3.87, respectively, from $54.0 million and $3.45. Additionally, we are increasing our adjusted EBITDA estimate to $38.5 million from $35.0 million. The upward revisions are driven by stronger-than-expected time charter equivalent (TCE) rates.
Full-year 2025 estimates. For the full-year 2025, we expect higher revenues and adjusted earnings per share estimates of $228.5 million and $15.47, respectively, up from $225.6 million and $15.05. We are raising our operating expense estimates to $83.0 million from $81.7 million, due to higher dry-docking expenses. Our full year adjusted EBITDA estimate has been increased to $153.1 million from $149.2 million. The increases in our estimates are largely due to higher TCE rates.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
EuroDry Ltd. was formed on January 8, 2018 under the laws of the Republic of the Marshall Islands to consolidate the drybulk fleet of Euroseas Ltd. into a separate listed public company. EuroDry was spun-off from Euroseas Ltd. on May 30, 2018; it trades on the NASDAQ Capital Market under the ticker EDRY. EuroDry operates in the dry cargo, drybulk shipping market. EuroDry’s operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company and Eurobulk (Far East) Ltd. Inc., which are responsible for the day- to-day commercial and technical management and operations of the vessels. EuroDry employs its vessels on spot and period charters and under pool agreements.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Second quarter estimates. We are lowering our Q2 2025 revenue and adjusted earnings per share estimates to $11.4 million and a loss of $1.23, respectively, from $14.1 million and a loss of $0.76. Additionally, we are reducing our operating expenses to $13.0 million from $14.4 million, as dry docking expenses have been pushed into the third quarter. Despite lower operating expenses, we are decreasing our adjusted EBITDA estimate to $1.6 million from $2.9 million. The decrease in our earnings estimates is mainly due to lower-than-expected time charter equivalent (TCE) rates.
Full-Year 2025 estimates. We are lowering our 2025 revenue and adjusted earnings per share estimates to $46.0 million and a loss of $4.41, respectively, from $50.3 million and a loss of $3.79. We are trimming our operating expenses to $51.4 million from $51.8 million, due to lower expected voyage expenses. Our adjusted EBITDA estimates were lowered to $5.6 million from $9.3 million. The lower estimates are driven by soft market rates.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Second quarter estimates. We are lowering our Q2 2025 revenue and adjusted earnings per share estimates to $11.4 million and a loss of $1.23, respectively, from $14.1 million and a loss of $0.76. Additionally, we are reducing our operating expenses to $13.0 million from $14.4 million, as dry docking expenses have been pushed into the third quarter. Despite lower operating expenses, we are decreasing our adjusted EBITDA estimate to $1.6 million from $2.9 million. The decrease in our earnings estimates is mainly due to lower-than-expected time charter equivalent (TCE) rates.
Full-Year 2025 estimates. We are lowering our 2025 revenue and adjusted earnings per share estimates to $46.0 million and a loss of $4.41, respectively, from $50.3 million and a loss of $3.79. We are trimming our operating expenses to $51.4 million from $51.8 million, due to lower expected voyage expenses. Our adjusted EBITDA estimates were lowered to $5.6 million from $9.3 million. The lower estimates are driven by soft market rates.
Updating second quarter estimates. We are raising our second quarter revenue and adjusted earnings per share estimates to $56.7 million and $3.87, respectively, from $54.0 million and $3.45. Additionally, we are increasing our adjusted EBITDA estimate to $38.5 million from $35.0 million. The upward revisions are driven by stronger-than-expected time charter equivalent (TCE) rates.
Full-year 2025 estimates. For the full-year 2025, we expect higher revenues and adjusted earnings per share estimates of $228.5 million and $15.47, respectively, up from $225.6 million and $15.05. We are raising our operating expense estimates to $83.0 million from $81.7 million, due to higher dry-docking expenses. Our full year adjusted EBITDA estimate has been increased to $153.1 million from $149.2 million. The increases in our estimates are largely due to higher TCE rates.
FreightCar America (RAIL/$11.54 | Price Target: $16) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Updating Our Forward Estimates and Increasing our PT Rating: OUTPERFORM
Increasing longer-term rail car delivery estimates. While we have maintained our rail car delivery estimates for 2025 through 2027, we have increased our delivery estimates for 2028 through 2030. We now forecast rail car deliveries of 5,500, 5,750, and 6,000, respectively, compared with our prior estimates of 5,000, 5,000, and 5,000. While we had previously assumed that RAIL would operate four production lines with an aggregate capacity of 5,000 rail cars through 2030, we now assume the company will operate five production lines with a total capacity of 6,250 rail cars beginning in 2028. Our prior assumption had been that the company could begin producing a new line of higher-margin tank cars using existing capacity at the expense of lower margin products. Because we think tank cars could add an incremental 500 or more orders beginning in 2028, the tank cars would be incremental to existing orders with five production lines.
Updating earnings estimates. We forecast 2025 EBITDA and EPS of $45.9 million and $0.47, respectively, while our 2026 estimates are $48.6 million and $0.53. While our 2025 and 2026 EBITDA estimates are unchanged, we have increased our forward estimates, which may be found in the financial model at the end of this report. While our earnings estimates have increased, gross margin as a percentage of sales remains unchanged at 13.0%, 13.3%, 13.5%, and 13.8% in 2027, 2028, 2029, and 2030, respectively, while selling, general, and administrative expense as a percentage of sales increased modestly.
Seanergy Maritime (SHIP/$7 | Price Target: $9) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Updating Estimates and Market Outlook Rating: OUTPERFORM
Second Quarter 2025 Estimate Revisions. We are raising our Q2 2025 net revenue forecast to $36.5 million from $35.9 million, driven by stronger-than-expected time charter equivalent (TCE) rates. However, we are lowering our adjusted EBITDA and EPS estimates to $16.7 million and $0.11, respectively, from $17.3 million and $0.17, reflecting higher operating expenses of $29.1 million versus $27.5 million previously. The increase reflects a full quarter of the expanded fleet as well as higher-than-expected dry-docking activity.
Full-Year 2025 Estimate Changes. We are increasing our 2025 revenue forecast to $143.4 million from $142.9 million, as we expect improving rate momentum to continue through year-end. We are also raising our operating expense estimate to $113.9 million from $109.4 million, reflecting a greater number of anticipated dry-docking days. As a result, we are lowering our adjusted EBITDA projection to $67.7 million from $70.5 million and our EPS estimate to $0.51 from $0.74.
Travelzoo (TZOO/$12.55 | Price Target: $26) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Steps On The Customer Acquisition Accelerator Rating: OUTPERFORM
Mixed second quarter results. Revenues significantly increased 13.1% to $23.9 million, a sequential quarterly increase from 5.3% in Q1, reflecting its strategic shift toward a subscription based model. Adj. EBITDA fell short of our expectations, however, due to a step up in customer acquisition spend and the purchase of “distressed” vouchers.
Favorable customer acquisition dynamics. Customer acquisition costs went up in Q2 to $38 from $28 in Q1, but still remains positive. Total return is $58, $40 from the annual subscription fee and $18 from transactions. Management anticipates to continue to aggressively spend on customer acquisition in light of the favorable Return on Investment. These moves support a longer term attractive revenue outlook, but have a near term adverse impact on adj. EBITDA.
Noble Capital Markets Research Report Wednesday, July 23, 2025
Companies contained in today’s report:
The Oncology Institute, Inc. (TOI)/OUTPERFORM – Improving Oncology Treatment While Cutting Costs
The Oncology Institute, Inc. (TOI/$3.54 | Price Target: $8) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Improving Oncology Treatment While Cutting Costs Rating: OUTPERFORM
Initiating Coverage of The Oncology Institute With An Outperform Rating. The Oncology Institute of Hope & Innovation (TOI) is a medical practice management company specializing in community-based oncology practices. It manages and operates oncology clinics in five states using its proprietary, value-based methodology. These treatment regimens have improved outcomes for patients while reducing the cost of care.
TOI Uses Capitated Contracts To Control Costs. TOI enters into contracts with third-party payers to treat a specified number of health plan members based on the estimated per-member, per-month cost. This method of providing coverage based on population size is known as capitation. It also offers traditional fee-for-service as well as value-based oncology care. This provides TOI with the flexibility to contract with more insurance plans.
Noble Capital Markets Research Report Tuesday, July 22, 2025
Companies contained in today’s report:
Century Lithium Corp. (CYDVF)/OUTPERFORM – Angel Island Lithium Carbonate Proves its Value Nicola Mining Inc. (HUSIF)/OUTPERFORM – Updating Our Sum-of-the-Parts Valuation; Raising Price Target
Century Lithium Corp. (CYDVF/$0.25 | Price Target: $2.35) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Angel Island Lithium Carbonate Proves its Value Rating: OUTPERFORM
Lithium-metal anodes. Century Lithium announced that Alpha-En Corporation successfully converted Century’s lithium carbonate into battery-grade lithium-metal anodes for use in lithium-ion batteries. The lithium-metal anodes were produced using 99.8% pure lithium carbonate from Century’s Angel Island project and demonstration plant. The sample was converted by Alpha-En into lithium metal using Alpha-En’s patented conversion process.
LFP 18650 battery cells. Earlier in the month, Century announced that First Phosphate Corp. produced commercial-grade lithium iron phosphate (LFP) 18650 battery cells using North American critical minerals, including lithium carbonate sourced from Century’s Angel Island project and demonstration plant, along with high-purity phosphoric acid and iron powder from First Phosphate’s Begin-Lamarche property in Quebec. The LFP 18650 battery cells were assembled for First Phosphate by Ultion Technologies at their pilot facility in Nevada.
The Merritt Mill is processing ore. Nicola Mining’s (TSX.V: NIM, OTCQB: HUSIF) 100% owned Merritt Mill in British Columbia recently began milling and processing ore from Talisker Resources Ltd.’s (TSX: TSK, OTCQX: TSKFF) Mustang mine to produce gold and silver concentrate. On May 11, Talisker began trucking material to the Craigmont Mill. The commencement of milling operations marked Nicola’s transition to a long-term production plan and sustained revenue and cash flow generation.
Flow-through financing. Nicola Mining raised gross proceeds of C$2,175,000 with a non-brokered private placement of 4,350,000 units at a price of C$0.50 per unit. Each unit consists of one flow-through common share and one-half of one non-flow-through common share purchase warrant. Each warrant is exercisable at a price of C$0.65 and expires two years from the date of issuance. The financing was oversubscribed by a total of 350,000 units or C$175,000. Proceeds will be used to fund exploration at the company’s New Craigmont Copper Project.
Noble Capital Markets Research Report Monday, July 21, 2025
Companies contained in today’s report:
InPlay Oil (IPOOF)/OUTPERFORM – Increasing Estimates and a First Look at 2026
InPlay Oil (IPOOF/$7.4 | Price Target: $15) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Increasing Estimates and a First Look at 2026 Rating: OUTPERFORM
Company strategy. Despite the recent improvement in oil prices, InPlay is maintaining its 2025 production guidance at 16,000 to 16,800 boe/d. Management reiterated that the strategy remains centered on capital discipline, prioritizing debt reduction over production growth. The company’s approach is supported by fluctuating oil prices and the performance of assets acquired from Obsidian Energy, which have demonstrated low decline rates and continue to well-exceed type curve expectations. Recall that as part of the transaction, Obsidian Energy received InPlay shares as part of the consideration.
Non-binding offer. InPlay Oil announced that Obsidian Energy has entered into a non-binding agreement with a third party for the sale of its entire position in InPlay, totaling 9,139,784 common shares. The proposed transaction is expected to occur at a premium to InPlay’s share price as of July 15, 2025. While the parties remain in discussions, no binding agreement has been finalized at this time.
Noble Capital Markets Research Report Friday, July 18, 2025
Companies contained in today’s report:
Bit Digital (BTBT)/OUTPERFORM – More News; Updated Model
Bit Digital (BTBT/$4.01 | Price Target: $5.5) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 More News; Updated Model Rating: OUTPERFORM
Updated Model. Earlier this week, Bit Digital announced preliminary revenue for 2Q25 in the $24.3-$26.9 million range, which is modestly below our and consensus estimates. The difference, in our view, is likely driven by the push to the right of some contracts. We are not too concerned as of now, as we expect the contracts to come online this year.
Adjusted Numbers. We lowered our 2Q revenue expectation to $25.3 million from a prior $31.6 million, with the biggest change coming in the Cloud Services and Mining line items. Net loss is now at $4.4 million, or $0.02/sh, versus a prior loss of $1.4 million, or $0.01/sh.
Noble Capital Markets Research Report Wednesday, July 16, 2025
Companies contained in today’s report:
Hemisphere Energy (HMENF)/OUTPERFORM – Extending a Track Record of Returning Capital to Shareholders SelectQuote (SLQT)/OUTPERFORM – Temporary Pressure, Strong Path Forward The GEO Group (GEO)/OUTPERFORM – Amends Senior Revolving Credit Facility
Hemisphere Energy (HMENF/$1.41 | Price Target: $2.4) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Extending a Track Record of Returning Capital to Shareholders Rating: OUTPERFORM
Special dividend. Hemisphere Energy declared a special dividend of C$0.03 per common share that is payable on August 15 to shareholders of record as of July 31. It is in addition to the company’s quarterly base dividend of C$0.025 per common share and is Hemisphere’s second special dividend payment in 2025.
Normal course issuer bid. Hemisphere Energy recently announced that the TSX Venture Exchange had accepted its notice to renew its Normal Course Issuer Bid (NCIB) to purchase for cancellation up to 7,934,731 common shares. Purchases will be made on the open market at prevailing market prices through the TSXV. The NCIB commenced on July 14, 2025, and will terminate on July 13, 2026.
SelectQuote (SLQT/$2.23 | Price Target: $7) Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Temporary Pressure, Strong Path Forward Rating: OUTPERFORM
Setting up fiscal 2026. We are adjusting our fiscal Q4 estimates to reflect updated expectations for the Medicare Advantage market, with a particular focus on recent regulatory changes affecting Special Needs Plans (SNPs). While these developments introduce near-term challenges, we believe SelectQuote is well-positioned heading into fiscal 2026. We expect the company to rebuild agent capacity ahead of the next Annual Enrollment Period (AEP), to support a trajectory of sustained revenue growth and adj. EBITDA margin expansion.
Special Needs changes. Our revised Q4 outlook is primarily driven by recent changes implemented by CMS that restructure Special Needs Plan switching rights. The policy shift narrows mid-year enrollment flexibility for a significant portion of dual-eligible consumers (those enrolled in non-integrated D-SNPs), leading to the prospect of a smaller pool of shopping beneficiaries during the middle of calendar 2025. In addition, we are accounting for SelectQuote’s reduced year-over-year agent count, which entered fiscal 2025 approximately 22% below the prior-year level due to capital constraints at the time. These factors combined create a more muted backdrop for near-term Medicare Advantage performance.
The GEO Group (GEO/$25.04 | Price Target: $35) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Amends Senior Revolving Credit Facility Rating: OUTPERFORM
Amended Facility. The GEO Group announced amendments to its April 2024 Credit Agreement that provide enhanced flexibility, better terms, and an extended maturity. Along with the additional payments on the outstanding debt, GEO has taken another step closer to being able to return capital to shareholders, in our view.
Details. The Amendment increases GEO’s revolver commitments from $310 million to $450 million and extends the maturity to July 14, 2030. The Amendment further provides that interest will accrue on outstanding revolving credit loans at a rate determined with reference to the Company’s total leverage ratio, which, as of today, reduces the rate by 0.50% from the prior applicable rate. The Amendment also increases GEO’s capacity to make restricted payments over the next five years.
Noble Capital Markets Research Report Tuesday, July 15, 2025
Companies contained in today’s report:
Lucky Strike Entertainment (LUCK)/OUTPERFORM – A Compelling Transaction
Lucky Strike Entertainment (LUCK/$10.29 | Price Target: $17.5) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | A Compelling Transaction Rating: OUTPERFORM
Purchases real estate. The company announced that it purchased the real estate of 58 existing bowling centers for $306 million from Carlyle Group, its main sale leaseback partner. The real estate is located in California, Illinois, Georgia, Arizona, and Colorado. With the purchase, the company now owns roughly 75 of its over 350 bowling centers.
Financing set. The company amended its existing credit facility to provide a bridge loan of $230 million towards the purchase. Cash was used for the remaining purchase amount. We believe that the company will reduce the bridge loan over the course of the next year through free cash flow generation.
First quarter financial results. For the first quarter of fiscal year (FY) 2026, AZZ reported adjusted net income of $53.8 million or $1.78 per share compared to $44.0 million or $1.46 per share during the prior year period and our estimate of $50.1 million or $1.66 per share. Compared to the first quarter of FY 2025, sales increased 2.1% to $422.0 million. Adjusted EBITDA increased 13.1% to $106.4 million, representing 25.2% of sales compared to 22.8% of sales during the prior year period.
Updating estimates. We have increased our FY 2026 EBITDA and EPS estimates to $388.3 million and $6.00, respectively, from $381.7 million and $5.83. In FY 2026, our estimates reflect average gross margins of 30.0% and 20.3% for the Metal Coatings and Precoat Metals segments, respectively. Moreover, we have published our estimates for 2027 through 2031 in the back of this report. Our forward estimates reflect an average 30.5% gross margin as a percentage of sales for the Metal Coatings segment, compared to the prior average of 28.0%. The average gross margin as a percentage of sales for the Precoat Metals business is unchanged at 20.3%.
Kratos Defense & Security (KTOS/$51.71 | Price Target: $60) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Fast Tracked Drone Opportunity; Raising PT Rating: OUTPERFORM
Directive. Building on President Trump’s June 6th Executive Order to Unleash American Drone Dominance, this past week Defense Secretary Hegseth signed a memo removing restrictive policies on drone innovation. By leveraging savings from DOGE, the DOD will help power a technological leapfrog and bolster the U.S. drone industry by approving hundreds of made-in-America drone products for purchase by the military. These goals play right into Kratos’ wheelhouse, in our view.
New Focus. The directive focuses on three key areas: strengthening the U.S. drone manufacturing base, arming combat units with a variety of low-cost drones, and ensuring those combat units are well-trained on how to use them. Kratos has been expanding its drone production capabilities, which the recent capital raise will turbocharge. Its drone technology is proven and available today, and the Company is the leader in providing target drones to the military.
Noble Capital Markets Research Report Thursday, July 10, 2025
Companies contained in today’s report:
AZZ (AZZ)/OUTPERFORM – Strong Start to Fiscal Year 2026 Eledon Pharmaceuticals (ELDN)/OUTPERFORM – Meeting Highlights Tegoprubart Data Milestones and New Indications
AZZ (AZZ/$100.73 | Price Target: $112) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Strong Start to Fiscal Year 2026 Rating: OUTPERFORM
FY 2026 first quarter financial results. AZZ reported adjusted net income of $53.8 million or $1.78 per share compared to $44.0 million or $1.46 per share during the prior year period. We had forecast adjusted net income of $50.1 million or $1.66 per share. Compared to the first quarter of FY 2025, sales increased 2.1% to $422.0 million. Adjusted EBITDA increased 13.1% to $106.4 million, representing 25.2% of sales compared to 22.8% of sales during the prior year period. We had projected adjusted EBITDA of $99.5 million.
Meaningful debt reduction. Cash from operations during the fiscal first quarter amounted to $314.8 million, including proceeds of $273.2 million received from AVAIL’s sale of the Electrical Products Group. Following debt reduction of $285.4 million, AZZ ended the quarter with a net leverage ratio of 1.7x TTM adjusted EBITDA. As of May 31, long-term debt, gross was $614.9 million compared to $900.3 million on February 28. Net of unamortized debt issuance costs, long-term debt was $569.8 million on May 31 compared to $852.4 million on February 28.
Eledon Pharmaceuticals (ELDN/$3.4 | Price Target: $10) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Meeting Highlights Tegoprubart Data Milestones and New Indications Rating: OUTPERFORM
R&D Day Highlighted Science, Current Trials, Future Indications. We attended the Eledon R&D Day on July 9 to hear and evaluate the progress in tegoprubart development. The presentations focused on the current clinical indications in renal transplantation, islet cell transplantation, xenotransplants, and plans for liver and other solid organ transplants. Conference presentation dates for upcoming data announcements were also announced.
Phase 1b Data Update Is Planned For August. The Phase 1b open-label trial has been expanded to enroll up to 36 patients, an increase from the original 9 patients. Data is scheduled for presentation at the World Transplant Congress on August 9, 2025. Previous data presentations have included 13 patients. We expect to see follow-up data from more patients treated longer, with data from additional patients beyond the initial 12-month trial duration.
Updating estimates. We are increasing our 2025 adjusted EBITDA and EPU estimates to $676.5 million and $2.55, respectively, from $672.6 million and $2.52. We increased our crude oil and natural gas price estimates based on CME futures settlements, which had a positive impact on oil and gas royalty revenue. Our 2026 adjusted EBITDA and EPS estimates are unchanged at $678.3 million and $2.60, respectively. While management expects the average coal sales price per ton to trend lower in 2026 due to higher-priced contracts rolling off, we think 2025 longwall moves and actions to improve productivity and cost effectiveness could help offset the impact of lower prices.
Recent legislation expected to benefit the fossil fuel industry. Following several executive orders earlier in the year intended to support the coal industry and delay coal power plant retirements, the Big Beautiful Bill (BBB) was signed into law on July 4 and is expected to benefit the fossil fuel industry. Among other things, the BBB phases out many of the clean energy tax credits established under the Inflation Reduction Act and creates a supportive environment for oil, gas, and coal production.
E.W. Scripps (SSP/$3.42 | Price Target: $10) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Strengthening Its Station Portfolio Rating: OUTPERFORM
Compelling station swap. Scripps will be selling its stations in Lansing MI and Lafayette LA to Gray Television (GTN: Not Rated) and buying stations in Colorado Springs, CO and Grand Junction, CO and a station in Twin Falls ID. We view the move favorably, given that Scripps will create station duopolies and strengthen its presence in the West. We believe that the move will create significant efficiencies for both companies, eliminating back office, duplicative, and overhead costs. This will be an even swap with no cash compensation to either party.
FCC fast track? The FCC has signaled its willingness to fast track the regulatory process, likely to provide a “waiver” to create duopolies rather than to seek a longer review/rulemaking process. As such, we believe that the transaction could be completed by year end.
Xcel Brands (XELB/$1.58 | Price Target: $9) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Seeking Fuel For Growth Rating: OUTPERFORM
Files S1. The company plans to sell 1.381 million shares on a “best efforts” basis and pre-funded warrants. Pre-funded warrants are exercisable at any time after the date of issuance and may be exercised at any time. Notably, management has indicated its interest in participating in the offering for up to 10% of the shares. Following the prospective sale, total shares outstanding would increase to 3.819 million shares.
Use of proceeds. Based on the current stock price and assuming all shares are sold, management expects to generate roughly $1.9 million in net proceeds from the offering. The company plans to use the proceeds for working capital and general corporate purposes and toward a $50,000 principal loan payment to a company controlled by Robert D’Loren, the company’s Chairman and CEO.
Noble Capital Markets Research Report Thursday, July 3, 2025
Companies contained in today’s report:
Commercial Vehicle Group (CVGI)/OUTPERFORM – A Debt Refi Government Solutions (Government Solutions) – CoreCivic and GEO poised to Benefit From Big Beautiful Bill MariMed Inc (MRMD)/OUTPERFORM – Rec Sales to Begin in Delaware ONE Group Hospitality (STKS)/OUTPERFORM – Diners Seeking “Uniqueness and Entertainment”
Commercial Vehicle Group (CVGI/$2 | Price Target: $4) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 A Debt Refi Rating: OUTPERFORM
Refi. Commercial Vehicle Group successfully refinanced its debt, extending the maturity out to 2030 from 2027. We believe this should provide the Company with additional financial flexibility as management continues to drive further operational efficiency.
Details. The Company went from an $85 million term loan to a $95 million term loan and from a $125 million ABL to a $115 million ABL. Proceeds were used to repay $120.1 million outstanding under the previous facility. The initial interest rate on the term loan is 9.75%, although future rates will have a tiered interest cost based on the consolidated leverage ratio. The initial ABL rate is SOFR plus 1.75%.
Government Solutions Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 CoreCivic and GEO poised to Benefit From Big Beautiful Bill
Big Beautiful Bill. The Senate version of the “One Big Beautiful Bill Act” aligns with or even improves upon the House version when it comes to spending on immigration. While it remains to be seen the exact version that will come out of the reconciliation process and be sent to President Trump for his signature, the proposed versions should prove to be beneficial to both CoreCivic and The GEO Group.
Detention Budget. Both the Senate and House proposals call for $45 billion of funding for detention capacity or an additional $10.6 billion annually through fiscal 2029. This would represent an over 300% increase over the current detention budget. This level of funding could support detention bed capacity in excess of 115,000 beds, up from a current 41,500.
MariMed Inc (MRMD/$0.08 | Price Target: $0.25) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Rec Sales to Begin in Delaware Rating: OUTPERFORM
Recreational Cannabis. After legislation approving recreational cannabis in April 2023, Delaware will finally commence sales of recreational cannabis on August 1st of this year. Legal recreational cannabis can be purchased in the 13 existing medical dispensaries as well as through the 30 recreational licenses the state has approved. We expect sales to be derived not only from the state population, many of whom currently travel to existing legal states such as Maryland and New Jersey to obtain the product, but also from the estimated 30 million tourists that visit the state annually.
Delaware Market. Delaware has had a medical market for a while. The market is estimated to be approximately $50 million in size, with flattish growth to 2029 when the medical is projected to rise to $55 million. The recreational cannabis market could grow to the $250-$300 million level, according to various government projections.
ONE Group Hospitality (STKS/$4.75 | Price Target: $5) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Diners Seeking “Uniqueness and Entertainment” Rating: OUTPERFORM
Diner Views. Today’s diners are seeking out venues that prioritize entertainment and uniqueness, according to a Yelp survey that analyzed consumer web searches from January to March. The Yelp findings are in-line with recent research by hospitality management platform SevenRooms. According to SevenRooms’ 2025 U.S. Restaurant Industry Trends, consumers who dine out value unique experiences, even at a premium, with 74% of consumers returning to a restaurant after a unique experience.
A Vibe Dining Leader. As a leader in Vibe Dining, ONE Hospitality is well positioned to capitalize on this trend through its portfolio of concepts, including chains STK, Benihana, Kona Grill, and RA Sushi, as well as the Salt Water Social and Samurai concepts. These upscale and polished casual, high-energy restaurants and lounges provide entertainment and unique experiences for diners, as well as one-of-a-kind, celebratory experiences that bring customers back.
Noble Capital Markets Research Report Wednesday, July 2, 2025
Companies contained in today’s report:
AZZ (AZZ)/OUTPERFORM – AZZ Acquires Canton Galvanizing, LLC GoHealth (GOCO)/OUTPERFORM – Credit Amendment Provides Reprieve Resources Connection (RGP)/OUTPERFORM – A Cooperation Agreement and New Directors The GEO Group (GEO)/OUTPERFORM – From Lease to Ownership
AZZ (AZZ/$96.74 | Price Target: $112) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 AZZ Acquires Canton Galvanizing, LLC Rating: OUTPERFORM
Bolt-on acquisition. AZZ Inc. entered into an agreement to acquire all the assets of Canton Galvanizing, LLC, a privately held hot dip galvanizing company based in Canton, Ohio. While the terms of the transaction were not disclosed, AZZ expects the transaction to be accretive to earnings within the first year of operation. Founded in 2019, Canton provides hot-dip galvanizing to customers in the U.S. Midwest and specializes in coating small to mid-size parts.
Strengthens AZZ’s presence in the U.S. Midwest. The strategic acquisition expands AZZ’s Metal Coatings capabilities in the US. Midwest and increases its total galvanizing network to 42 sites in North America. It has been renamed AZZ Galvanizing – Canton East LLC. With a spinning operation and a 21-foot kettle, Canton is known for quick turnaround times and excellent customer service.
GoHealth (GOCO/$5.92 | Price Target: $25) Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Credit Amendment Provides Reprieve Rating: OUTPERFORM
Amended credit agreement. On June 30, the company announced an amendment to its credit agreement, extending the maturity of the company’s Class A Revolving Commitments from Q2 end to Q3 end. Moreover, any interest due on the revolver and refinanced term loans through that date will be paid in-kind. The amendment also waived financial covenant testing for Q2 and Q3, offering the company a temporary liquidity reprieve.
Cost of amendment. As part of the amendment, GoHealth will pay a 1.00% amendment fee to consenting lenders, which, along with all interest through September 30, will be paid in-kind and added to the principal balance of its loans. As a result, we estimate these provisions will increase the company’s outstanding debt by approximately $6 million.
Resources Connection (RGP/$5.76 | Price Target: $15) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Jacob Mutchler jmutchler@noblefcm.com | A Cooperation Agreement and New Directors Rating: OUTPERFORM
Cooperation Agreement. Resources Connection has entered into a “Cooperation Agreement” with shareholder Circumference Group LLC. According to a Form 3 filing of June 30th, Circumference owns 1,289,243 RGP shares, representing 3.9% of the common shares outstanding as of March 31st.
Board Changes. As part of the Cooperation Agreement, RGP appointed Jeff Fox, founding partner and CEO of Circumference Group, and Filip Gyde, former CEO of Computer Task Group, to the Board. Current Board members Anthony Cherbak and Neil Dimick will retire from the Board following the conclusion of their terms in October 2025.
The GEO Group (GEO/$24.49 | Price Target: $35) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 From Lease to Ownership Rating: OUTPERFORM
A Purchase. The GEO Group is purchasing the currently leased 770-bed Western Region Detention facility for $60 million, or $77,900/bed. GEO is currently leasing the facility at a cost of $5.1 million annually. GEO has had a long-term contract with the U.S. Marshals Service for use of the facility, which generates approximately $57 million of annualized revenue.
A Tax Savings. Expected to close by the end of July, the transaction is expected to be funded as a like kind real estate property exchange with proceeds from the previously announced sale of the GEO-owned Lawton Correctional Facility, which is expected to close on July 25th, resulting in an estimated capital gains cash tax savings of approximately $9.5 million.
Noble Capital Markets Research Report Tuesday, July 1, 2025
Companies contained in today’s report:
Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – Some Award Updates Kratos Defense & Security (KTOS)/OUTPERFORM – Completes $575 Million Capital Raise Unicycive Therapeutics (UNCY)/OUTPERFORM – CRL Letter Received As Second Manufacturer Generates Data
Great Lakes Dredge & Dock (GLDD/$12.19 | Price Target: $14) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Some Award Updates Rating: OUTPERFORM
Awards. Yesterday, Great Lakes provided an update on some recent awards. Each of the awards adds to the Company’s significant backlog, which stood at approximately $1 billion with an additional $265 million in low bids and options pending award at the end of the first quarter. The large backlog, with a majority being higher margin capital projects, provides strong visibility for 2025 and into 2026.
Woodside LNG. The Company received Notice to Proceed from Bechtel Energy for dredging work on the Woodside Louisiana LNG project. The first phase of work, which was awarded in the second quarter of 2025, includes the construction of a ship berthing basin for use by large LNG carriers, with potential for award of two options to expand the scope of construction for additional ship berths. Dredging operations are expected to commence in early 2026.
Kratos Defense & Security (KTOS/$46.45 | Price Target: $44) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Completes $575 Million Capital Raise Rating: OUTPERFORM
Capital Raise. Kratos completed its previously announced offering of Kratos common stock, raising $575 million in gross proceeds, at a public offering price of $38.50 per share, for a total of 14,935,065 shares of common stock, which includes the exercise of the underwriter’s option to purchase additional shares. Net proceeds from the offering were approximately $556 million. Noble Capital participated as a co-manager of the offering.
Use of Proceeds. Kratos expects to use the net proceeds of the offering to (i) fund investments and capital expenditures to scale and successfully execute on large, mission critical National Security priorities related to existing programs, recent program awards and significant high-probability pipeline opportunities; (ii) to finance important customer and program targeted acquisitions; (iii) and for general corporate purposes.
Unicycive Therapeutics (UNCY/$4.77 | Price Target: $60) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 CRL Letter Received As Second Manufacturer Generates Data Rating: OUTPERFORM
Approval Delay Is Not A Surprise. Unicycive announced that it has received a Complete Response Letter (CRL) in response to its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC). This was expected following the announcement earlier this month stating that the FDA manufacturing inspection had found deficiencies with one of the OLC contract manufacturers. The company has switched to one of its other manufacturers, which we believe can resolve the issues quickly. We see approval possible around 4Q25 to 1Q26.
Plans To Address The Issues. Unicycive plans to hold a Type A meeting with the FDA to determine its requirements for resolution of the issues cited in the CRL. The company’s second manufacturer already produces OLC and has been generating data for FDA certification. This should allow Unicycive to submit any additional data requested quickly to resolve the issue.
Noble Capital Markets Research Report Monday, June 30, 2025
Companies contained in today’s report:
Aurania Resources (AUIAF)/OUTPERFORM – Promising New Data Highlights the Potential for a Significant Copper Discovery
Aurania Resources (AUIAF/$0.17 | Price Target: $0.5) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Promising New Data Highlights the Potential for a Significant Copper Discovery Rating: OUTPERFORM
Application of two-dimensional inversion technology. Aurania Resources announced that six highly conductive anomalies have been revealed at the company’s Awacha porphyry copper target based on reprocessed data from a 2021 mobile magnetotellurics (MobileMT) survey using the latest two-dimensional (2D) inversion technology. Compared to the previously employed 1D algorithm, the 2.5D code accounts for the actual topography of the area, resulting in more accurate mapping of subsurface conductivity.
Six promising anomalies at Awacha. New inversion data has confirmed the presence of six high-conductivity anomalies that begin 250 meters from the surface and exhibit deep roots. The anomalies are of significant interest because zones of elevated conductivity often correlate with porphyry copper deposits due to the presence of conductive sulphide minerals and porphyry-related alteration.
Noble Capital Markets Research Report Friday, June 27, 2025
Companies contained in today’s report:
AZZ (AZZ)/OUTPERFORM – Quarterly Cash Dividend Increased by 17.6%, 1Q FY2026 Financial Results to be Released on July 9 Bit Digital (BTBT)/OUTPERFORM – A Flurry of News Steelcase (SCS)/OUTPERFORM – Post Call Commentary V2X (VVX)/OUTPERFORM – An $118 Million Contract
AZZ (AZZ/$92.75 | Price Target: $112) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Quarterly Cash Dividend Increased by 17.6%, 1Q FY2026 Financial Results to be Released on July 9 Rating: OUTPERFORM
Increase in the quarterly cash dividend. AZZ announced a 17.6% increase in the quarterly cash dividend to $0.20 per share, or $0.80 on an annualized basis, from $0.17 per share, or $0.68 on an annualized basis. The dividend is payable on July 31 to shareholders of record as of the close of business on July 10. In our view, the dividend increase reflects management’s confidence in the company’s near- and long-term outlook.
First Quarter FY 2026 financial results. AZZ will release its first quarter financial results after the market close on Wednesday, July 9. Management will host an investor conference call and webcast on Thursday, July 10, at 11:00 am ET. We look forward to an update regarding the company’s new aluminum coil coating facility in Washington, Missouri, that is ramping up production, along with a review of market fundamentals and the company’s capital allocation priorities.
Bit Digital (BTBT/$1.99 | Price Target: $5.5) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 A Flurry of News Rating: OUTPERFORM
News. Bit Digital released a flurry of news over the past two days, including a strategic shift in its business strategy, the potential IPO of its WhiteFiber subsidiary, and a $150 million equity offering. Needless to say, a lot to digest. If completed, the announced shifts would result in a significant change to Bit Digital.
Ethereum Focus. Operationally, Bit Digital will exit the bitcoin mining business and transition to become a pure-play Ethereum staking and treasury company. Given the economics of bitcoin mining versus Ethereum staking, we see the rationale in the move. The Company has commenced a strategic alternatives process for the Bitcoin mining operations.
Steelcase (SCS/$10.89 | Price Target: $16) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Post Call Commentary Rating: OUTPERFORM
Mixed Environment. Steelcase continues to face a mixed environment, both on a vertical basis and a geographical basis. The key large corporate customer cohort is doing well, driven by a number of factors such as return to office, but education and government have been hit by funding uncertainties. Germany and France remain sluggish in the key small-to-mid-sized business, but India and China are doing better.
International Actions. Steelcase is taking steps to implement additional cost reduction efforts in Europe, given the weak macroeconomic factors and lower demand in France and Germany. A goal of these actions is to get the International segment back to profitability.
V2X (VVX/$48.47 | Price Target: $72) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 An $118 Million Contract Rating: OUTPERFORM
Support Services. According to the daily Department of Defense contract announcements, V2X subsidiary Vectrus Systems has been awarded an $118 million cost-plus-fixed-fee undefinitized contract for base support services in support of the Iraq F-16 program. This is another in a long line of recent wins for V2X, demonstrating the V2X value proposition and confirming the significant traction on near-term Foreign Military and International opportunities previously highlighted by management.
Details. The contract provides for base operating support, base life support, and security services. Work will be performed at Martyr BG Ali Flaih Air Base, Iraq, and is expected to be completed by Nov. 30, 2026. This contract involves Foreign Military Sales (FMS) to Iraq. This contract was a sole source acquisition. FMS funds in the amount of $57.8 million are being obligated at the time of award.
Noble Capital Markets Research Report Thursday, June 26, 2025
Companies contained in today’s report:
Steelcase (SCS)/OUTPERFORM – First Look At A Solid First Quarter
Steelcase (SCS/$10.62 | Price Target: $16) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 First Look At A Solid First Quarter Rating: OUTPERFORM
1Q26. Steelcase reported solid results for the first quarter of fiscal 2026. Revenue grew 7% y-o-y to $779 million, towards the upper end of guidance. We had forecast $760 million and the consensus was $762 million. Gross margin of 33.9% was up 170 bp y-o-y and above management’s 33% guide. Steelcase reported net income of $13.6 million, or EPS of $0.11, and adjusted EPS of $0.20, compared to $10.9 million, $0.09, and $0.16, respectively, last year. We were at adjusted EPS of $0.14, while consensus was $0.13.
Quarterly Drivers. The Americas business was up 9%, both on a reported and organic basis, driven by a higher beginning backlog compared to the prior year and included strong growth from large corporate, government, and healthcare customers. International was up 1% on a reported basis but down 1% on an organic basis, driven by declines in Germany and France, mostly offset by growth in India, the UK, and China.
Noble Capital Markets Research Report Wednesday, June 25, 2025
Companies contained in today’s report:
Comstock (LODE) /MARKET PERFORM – Strategic Partnership with Virtus Renewables
Comstock (LODE/$3.55) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Strategic Partnership with Virtus Renewables Rating: MARKET PERFORM
Strategic partnership with Virtus. Comstock Metals forged a strategic partnership with Virtus Renewables Service Group Inc. Comstock and Virtus will jointly develop and deliver comprehensive recycling, decommissioning, and logistics solutions designed to suit the specific needs of the renewable energy markets. The partnership enables a systemwide service offering with expanded industry reach to offer environmentally conscious solutions for renewable energy clients across the United States.
Mutual benefits. Virtus offers a comprehensive suite of operations, project management, and maintenance services for solar and battery storage projects. Combining Virtus’s end-to-end renewable energy service expertise with Comstock’s industry-leading, zero-landfill solution enhances its ability to serve the renewable energy market and benefit from a full lifecycle certification process that adheres to the highest standards of sustainability, reliability, and service. Comstock is the first solar panel recycling company in North America to be certified by Sustainable Electronics Recycling International (SERI) to the R2v3/RIOS Responsible Recycling Standard.
Noble Capital Markets Research Report Tuesday, June 24, 2025
Companies contained in today’s report:
Bit Digital (BTBT)/OUTPERFORM – New Credit Agreement Bitcoin Depot (BTM)/OUTPERFORM – Potential Fuel for Growth Ocugen (OCGN)/OUTPERFORM – Merger Agreement Moves NeoCart Into A New Company QuoteMedia Inc. (QMCI)/OUTPERFORM – Raising Price Target On Favorable Outlook
Bit Digital (BTBT/$2.32 | Price Target: $5.5) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Jacob Mutchler jmutchler@noblefcm.com | New Credit Agreement Rating: OUTPERFORM
Credit Agreement. Yesterday, Bit Digital’s WhiteFiber subsidiary announced a CAD$60 million credit facility with Royal Bank of Canada (RBC). We view this step favorably, as the facility not only provides funds to support the continued buildout of WhiteFiber’s Tier-3 AI data center portfolio but also is a confirmation of Bit Digital’s AI business model, in our view.
Terms. While we expect an 8-K to be filed with a full accounting of the terms, the credit agreement is among RBC and ENOVUM Data Centers Corp. and its Montreal II project as borrowers and guarantors, and is non-recourse to WhiteFiber or Bit Digital. It encompasses a real estate term loan, equipment financing, and a revolving facility. The facilities carry interest rates of CORRA plus 250 bps and a 3-year term.
Bitcoin Depot (BTM/$5.35 | Price Target: $9) Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Potential Fuel for Growth Rating: OUTPERFORM
Shelf registration. On June 20, the company filed a registration statement with the SEC for a $100 million mixed securities shelf registration, which could include Class A common stock, preferred shares, warrants, and units. The registration statement also included an at the money (ATM) sales agreement, which will allow the company to sell up to $50 million in class A common shares directly into the market.
Bolstering capital availability. We view the registration positively, as it provides the company with flexibility to raise capital opportunistically based on market conditions and the strength of BTM’s share price, which is up approximately 230% year-to-date. Importantly, this added capital access could support strategic initiatives such as tuck-in acquisitions or the purchase of additional kiosks, positioning the company to accelerate its network expansion and long-term revenue growth trajectory.
Ocugen (OCGN/$0.98 | Price Target: $8) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Merger Agreement Moves NeoCart Into A New Company Rating: OUTPERFORM
NeoCart Transferred To Form New Regenerative Medicine Company. Ocugen has announced that it has entered into a merger agreement with Carisma Therapeutics to form a new company. Ocugen will transfer its wholly-owned regenerative medicine division, OrthoCellix, including NeoCart, an autologous cartilage implant technology that uses a patient’s cells to repair articular cartilage defects in the knee. The all-stock transaction is valued at $150 million, with Ocugen shareholders owning 90% of the new company.
We Expect The New Company To Accelerate NeoCart Development. Ocugen has been refining the Phase 3 trial design and has planned to start Phase 3 trials during FY2025. NeoCart has received Regenerative Medicine Advanced Therapy (RMAT) designation, which accelerates BLA review and could lead to faster approval. While the NeoCart data has been strong, NeoCart was a legacy product that was acquired by Ocugen as part of its 2019 reverse merger with Histogenics. Regenerative medicine is outside Ocugen’s main focus, and we believe it can be developed more rapidly by a company focused on regenerative medicine.
QuoteMedia Inc. (QMCI/$0.16 | Price Target: $0.23) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Raising Price Target On Favorable Outlook Rating: OUTPERFORM
Solid Q1 Results. The company reported solid Q1 results, with revenue growing 3% over the prior year period to $4.8 million, marking the highest quarterly revenue in the company’s history. Adj. EBITDA of $0.4 million in Q1 was moderately lower than our estimate of $0.5 million estimate. We believe its business pipeline appears to be improving and should gain momentum throughout the year and into 2026.
Capitalizing less development costs. Notably, the company capitalized less development costs in Q1 than in prior quarters, leading to more development costs expensed in Q1. While this impacted Q1, we believe that margins should improve as the company begins to recognize the revenue from the new business “wins” in future quarters. Furthermore, the company will be expensing development costs at a similar rate to Q1 moving forward.
Noble Capital Markets Research Report Monday, June 23, 2025
Companies contained in today’s report:
Nicola Mining Inc. (HUSIF)/OUTPERFORM – Nicola Commences 2025 New Craigmont Exploration Drilling
Nicola Mining Inc. (HUSIF/$0.51 | Price Target: $0.5) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Nicola Commences 2025 New Craigmont Exploration Drilling Rating: OUTPERFORM
New Craigmont drilling program. Nicola Mining (TSX.V: NIM, OTCQB: HUSIF) has commenced the 2025 exploration and diamond drilling program at its New Craigmont Copper Project, which will entail 4,000 to 5,000 meters of drilling. The program is expected to run from June through September and cost $1.5 million to $2.0 million. The purpose of the 2025 program is to collect geological data for target development for a potential porphyry copper system at New Craigmont.
Identifying targets using artificial intelligence. In collaboration with ALS Geoanalytics (formerly ALS GoldSpot), five priority targets, three of which are included in the 2025 program, were identified using artificial intelligence (AI)-based methods to analyze and correlate geophysical and geochemical data from Nicola’s exploration data. The collaboration harnesses the power of AI to identify high-potential targets which could increase the probability of successful outcomes.
Noble Capital Markets Research Report Friday, June 20, 2025
Companies contained in today’s report:
Euroseas (ESEA)/OUTPERFORM – Strong Start to 2025 MAIA Biotechnology (MAIA)/OUTPERFORM – Roche Forms Agreement For THIO Combination Studies Nutriband (NTRB)/OUTPERFORM – Manufacturing Milestone Allows Development To Move Forward As Expected
Euroseas (ESEA/$45.69 | Price Target: $53) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Strong Start to 2025 Rating: OUTPERFORM
First quarter 2025 financial results. Euroseas Ltd. reported adjusted EBITDA and earnings per share (EPS) of $37.1 million and $3.76, respectively, compared to $24.6 million and $2.66 during the prior year period. Revenue increased due to a higher average number of vessels compared to the same period last year, while operating expenses declined. We had projected adjusted EBITDA and EPS of $34.7 million and $3.35, respectively. Relative to our estimates, revenues were higher, based on an average daily time charter equivalent rate of $27,806, versus our estimate of $26,221, while operating expenses were lower. Vessel operating expenses totaled $12.3 million compared to our estimate of $13.3 million.
Market outlook. The containership sector may face some challenges, including the potential for transit to resume through the Suez Canal, weaker economic conditions due to fluid trade policies, and a high industry order book, which could increase the supply of vessels. However, the company’s strong charter coverage through 2026 could insulate it from the potential for lower rates. Moreover, the feeder and intermediate segments of the market have relatively low order books, and demand for vessels remains strong.
MAIA Biotechnology (MAIA/$1.8 | Price Target: $14) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Roche Forms Agreement For THIO Combination Studies Rating: OUTPERFORM
MAIA Makes Its Third Supply Agreement. MAIA announced that it has entered a supply agreement with Genentech/Roche to test THIO (ateganosine) in combination with Tecentriq (atezolizumab, Roche’s PD-L1 checkpoint inhibitor) for the treatment of several hard-to-treat cancers. MAIA now has supply agreements to test THIO in combination with checkpoint inhibitors from three global pharmaceutical companies, which we see as an indicator of interest for future partnerships.
PD-1 or PD-1L? That Is The Question. Checkpoint inhibitors block the interaction of the surface proteins PD-1 (programmed death receptor-1) with PD-1L (the programed death receptor-1 ligand). When the PD-1 receptor binds to the PD-1L ligand, it inhibits the immune response. Checkpoint inhibitors are monoclonal antibody drugs against PD-1 or PD-L1 that block this interaction, allowing cancer cells to be recognized by a patient’s immune system and killed.
Nutriband (NTRB/$7.79 | Price Target: $15) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Manufacturing Milestone Allows Development To Move Forward As Expected Rating: OUTPERFORM
Preparing For AVERSA Fentanyl Clinical Testing. Nutriband and its partner Kindeva announced that it has completed commercial manufacturing processes and scale-up for AVERSA Fentanyl, its abuse-deterrent fentanyl patch. This allows the company begin manufacturing clinical supplies and filing the IND (Investigational New Drug application) for the Phase 1 clinical study within the timeframe we anticipated. Only a single Phase 1 study is needed to file the application for marketing approval.
Manufacturing Completion Is A Significant Milestone. This scale-up is a significant step that demonstrates the ability to apply Kindeva’s transdermal patch technology for commercial scale production of AVERSA Fentanyl patches. We expect the IND filing to be completed shortly, with clinical testing to follow as expected.
Noble Capital Markets Research Report Wednesday, June 18, 2025
Companies contained in today’s report:
GoHealth (GOCO)/OUTPERFORM – Noble Virtual Conference Highlights Vince Holding Corp. (VNCE)/OUTPERFORM – Mitigates Tariff Risks Much Faster Than Expected
GoHealth (GOCO/$5.46 | Price Target: $25) Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Noble Virtual Conference Highlights Rating: OUTPERFORM
Highlights from Noble’s Emerging Growth Virtual Conference. Vijay Kotte, CEO, presented at Noble’s Virtual Equity conference June 4 & 5th. Mr. Kotte highlighted the company’s proprietary technology, consumer-centric Medicare policy platform, and gave an update on recent developments. A rebroadcast is available here.
Purpose-built technology. Mr. Kotte emphasized the company’s use of proprietary machine learning tools alongside licensed agents to tailor recommendations to each consumer’s needs. With Medicare beneficiaries typically choosing from 40–50 plans, this technology plays a key role in efficiently identifying the most suitable options.
Vince Holding Corp. (VNCE/$1.48 | Price Target: $2.5) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Mitigates Tariff Risks Much Faster Than Expected Rating: OUTPERFORM
Solid Q1 results. the company reported Q1 revenue of $57.9 million and an adj. EBITDA loss of $3.0 million, both of which were better than our estimates of $56.0 million and a loss of $5.5 million, respectively. Notably, while revenue and adj. EBITDA are both modestly lower than the prior year period; we view the Q1 results favorably, given the company’s ability to manage the uncertain tariff outlook.
Tariff mitigation. The company highlighted that it has been taking steps to reduce its exposure to China, currently roughly 60% of its cost of goods sold. Notably, the company is sourcing from other countries and expects that China will be roughly 25% of its cost of goods by the end of 2025. The company has leadership located in the sourcing countries to ensure product quality.
Noble Capital Markets Research Report Tuesday, June 17, 2025
Companies contained in today’s report:
GeoVax Labs (GOVX)/OUTPERFORM – EMA Allows GEO-MVA To Leapfrog To Phase 3 Trial In EU Kratos Defense & Security (KTOS)/OUTPERFORM – New Award and Expansion; Raising PT Ocugen (OCGN)/OUTPERFORM – Stargardt Disease Program Moves To Phase 2/3 Trial SKYX Platforms (SKYX)/OUTPERFORM – Noble Virtual Conference Highlights The GEO Group (GEO)/OUTPERFORM – New USMS Transportation Contract
GeoVax Labs (GOVX/$1.32 | Price Target: $10) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 EMA Allows GEO-MVA To Leapfrog To Phase 3 Trial In EU Rating: OUTPERFORM
GEO-MVA Gets An Accelerated Pathway To European Approval. GeoVax announced that it has received guidance from the EMA (European Medicines Agency) that provides an accelerated path to approval for GEO-MVA, its modified vaccinia ankara (MVA) based vaccine for smallpox/Mpox. It will only be required to conduct immune-bridging and toxicity studies before moving directly to Phase 3. This cuts several years from development time and saves many millions of dollars in clinical expenses.
Only Phase 3 Will Be Needed. The Committee for Medicinal Products for Human Use (CHMP) of the EMA stated that only requirements before beginning a Phase 3 study will be a non-clinical immuno-bridging and toxicity studies. No Phase 1 or Phase 2 studies are required. An MAA regulatory application can be submitted after a single, Phase 3 immuno-bridging study against the approved MVA vaccine (Imvanex or Jynneos, from Bavarian Nordic). The proposed endpoints of the study would be demonstration of immunogenicity to show non-inferiority.
Kratos Defense & Security (KTOS/$41.21 | Price Target: $44) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Hans Baldau hbaldau@noblefcm.com | New Award and Expansion; Raising PT Rating: OUTPERFORM
New Award. Kratos was awarded a $25 million task order under the Command and Control System-Consolidated Sustainment and Resiliency contract with the U.S. Space Force Space Systems Command to support ground system capabilities for Evolved Strategic Satellite Communications (ESS). The ESS system will provide the survivable and endurable satellite communications capability for the Nuclear Command, Control, and Communications mission in all operational environments.
Details. The task order has a 34-month period of performance, which began on March 14th and will conclude on November 30, 2027. This was accomplished under the C-SAR single-award indefinite delivery/indefinite quantity (IDIQ) contract awarded to Kratos on November 15, 2023. The C-SAR IDIQ contract has a maximum value of $579 million to cover task/delivery orders to support operations, sustainment, enhancements, and constellation capacity.
Ocugen (OCGN/$1.16 | Price Target: $8) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Stargardt Disease Program Moves To Phase 2/3 Trial Rating: OUTPERFORM
OCU410ST Cleared To Begin Confirmatory Trial. Ocugen announced that the FDA has approved its IND amendment to allow OCU410ST to begin its Phase 2/3 pivotal confirmatory trial. This will become the second Ocugen product to move into a Phase 2/3 confirmatory trial, and keeps the company on schedule to meet its goal of submitting three BLAs in the three years between 2026-28.
Brief Description of Stargardt Disease. Stargardt disease is a rare autosomal recessive disease caused by mutations in the ABCA4 gene in the retina. Progressive loss of photoreceptor cells in the retina typically starts at a young age, leading to blindness. Ocugen has received Orphan Drug designation and Rare Pediatric Disease Designation (RPDD) for diseases associated with ABCA4 diseases, including Stargardt, retinitis pigmentosa 19, and cone-rod dystrophy 3.
SKYX Platforms (SKYX/$1.26 | Price Target: $5) Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Noble Virtual Conference Highlights Rating: OUTPERFORM
Highlights from Noble’s Emerging Growth Virtual Conference. Lenny Sokolow, Co-CEO, presented at Noble’s Virtual Equity conference June 4 & 5th. Mr. Sokolow discussed the company’s innovative technology, commercial partnerships, and its quest for mandatory standardization with the NEC, among other topics. A rebroadcast is available here.
Mandatory standardization efforts getting a boost. Management remains optimistic about its push for mandatory standardization, citing recent backing from a prominent government safety leader. The company’s “Code Team” expects further support from key safety organizations to advance its ceiling receptacle technology as a regulatory standard.
The GEO Group (GEO/$24.9 | Price Target: $35) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 New USMS Transportation Contract Rating: OUTPERFORM
USMS Contract. The GEO Group, through its GEO Transport subsidiary, has entered into a new 5-year contract, including option periods, with the U.S. Marshals Service (USMS) for the provision of secure transportation and contract detention officer services across three service regions covering 26 federal judicial districts and spanning 14 states. The new contract highlights the Company’s diversified service platform, in our view, which provides the Company with numerous growth avenues.
Impact. The new contract is expected to generate up to approximately $147 million over the five-year period, or up to approximately $29 million in annualized revenues per full-year of operations, with margins consistent with GEO’s Managed-Only services contracts, which average approximately 15%.
Noble Capital Markets Research Report Monday, June 16, 2025
Companies contained in today’s report:
Sky Harbour Group (SKYH)/OUTPERFORM – Noble Virtual Conference Highlights Superior Group of Companies (SGC)/OUTPERFORM – Noble Virtual Conference Highlights Travelzoo (TZOO)/OUTPERFORM – A New Addition To The Russell
Sky Harbour Group (SKYH/$9.73 | Price Target: $23) Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Noble Virtual Conference Highlights Rating: OUTPERFORM
Highlights from Noble’s Emerging Growth Virtual Conference. Tim Herr, Senior Vice President of Finance, presented at Noble’s Virtual Equity conference June 4 & 5th. Mr. Herr highlighted the company’s high-margin leasing model, market opportunity, and strategic initiatives. A rebroadcast is available here.
Attractive unit economics driven by high-margin lease model. Sky Harbour secures long-term airport ground leases at highly favorable rates, often below $1 per square foot annually. Although only 25–33% of each site is convertible into revenue-generating hangar space, that portion can lease for $40 or more per square foot, creating a substantial economic spread.
Superior Group of Companies (SGC/$9.79 | Price Target: $16) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Noble Virtual Conference Highlights Rating: OUTPERFORM
Highlights its investment merits. On June 5, the company presented at the Noble Virtual Conference to the investment community. The presentation conducted by Michael Benstock, CEO, and Mike Koempel, CFO, highlighted the company’s diverse business segments, favorable history of growth, and solid financial position. A replay of the presentation is available for viewing here.
Diverse business segments. The company operates three distinct business segments: Healthcare Apparel, Branded Products, and Contact Centers. Importantly, all three of the company’s segments have favorable organic growth opportunities, are profitable, and have compelling acquisition target opportunities. Furthermore, the company has a solid history of growth, with consolidated revenue growing at an 8% CAGR from 2019 through 2024.
Travelzoo (TZOO/$12.5 | Price Target: $28) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | A New Addition To The Russell Rating: OUTPERFORM
Joining the Russell. On June 10, the company announced that it is expected to join the Russell 3000 Index at market open on June 27. Notably, membership in the Russell 3000 Index, which remains active for one year, provides the company with automatic inclusion in the Russell 2000 Index.
Improved share visibility. In our view, joining the Russell Indices could provide a meaningful impact for the TZOO shares. Notably, we believe the inclusion in the Russell indices is likely to enhance the company’s share visibility among institutional investors and has the potential to increase trading volume, improve share liquidity, and introduce new investors to the company. As such, we view the development favorably.
Key Points: – Azoria Capital sues the Federal Reserve, demanding public access to FOMC meetings. – The lawsuit challenges the Fed’s closed-door practices under a 1976 federal law. – Rising political pressure may reshape how investors engage with monetary policy decisions.
In a dramatic turn that could upend decades of Federal Reserve protocol, asset manager Azoria Capital filed a lawsuit Thursday demanding the central bank’s monetary policy meetings be opened to the public. The suit, lodged in a Washington, D.C. federal court, accuses the Fed’s Federal Open Market Committee (FOMC) of violating a 1976 transparency law by continuing to hold closed-door deliberations.
The timing couldn’t be more critical. The FOMC is set to meet July 29–30, and Azoria is seeking a temporary restraining order that would force those discussions—typically among the most market-sensitive of any U.S. institution—into the public sphere.
Behind the suit is James Fishback, Azoria Capital’s CEO and a figure closely tied to the Trump administration. Fishback contends the FOMC’s secrecy isn’t just outdated—it’s damaging. “By operating beyond public scrutiny, the FOMC is deliberately undermining the accountability envisioned by Congress,” the lawsuit claims, adding that real-time access to Fed discussions would give investors critical tools to navigate volatility sparked by monetary shifts.
The move comes as President Trump, currently touring the Fed’s $2.5 billion refurbishment project in Washington, escalates his criticism of central bank leadership. Trump has long accused Chair Jerome Powell and other officials of keeping interest rates unnecessarily high—claims echoed in Azoria’s filing, which alleges the Fed’s policy stance is “politically motivated” and intended to sabotage the administration’s economic agenda.
While the Fed hasn’t raised rates during Trump’s term so far, it has also declined to cut them, preferring to take a wait-and-see approach to assess the impact of new trade and fiscal policies. Yet that inaction has drawn ire from two sides—those demanding tighter control of inflation and those, like the administration, calling for looser credit to fuel growth.
Market reaction to the lawsuit has been cautious but curious. The idea of live-streamed or even partially open FOMC meetings could fundamentally alter the pace at which market participants digest rate signals. That shift could lead to sharper intraday volatility but also present opportunities for nimble traders and small-cap managers who thrive in environments of rapid change.
For investors in the middle market and beyond, the lawsuit underscores a growing theme: political and legal challenges are no longer background noise—they are becoming tradable events. Should Azoria’s case gain traction, it could pave the way for real-time transparency around monetary policy, potentially giving smaller firms an edge over traditional gatekeepers.
Whether or not the courts side with Azoria, the message is clear—investors are demanding a seat at the Fed’s table. And in a climate where every basis point counts, that demand might just get louder.
Amazon is stepping back into the wearables game — but this time, it’s not about fitness tracking. The tech giant is acquiring Bee, an AI-powered bracelet startup whose smart device transcribes user conversations, makes them searchable, and turns those interactions into actionable content like to-do lists and reminders.
The acquisition was announced by Bee CEO Maria de Lourdes Zollo on LinkedIn Tuesday, with confirmation from Amazon shortly after. While financial details remain undisclosed and the deal hasn’t yet officially closed, the implications are clear: Amazon wants to push deeper into personal AI, and Bee’s technology may become a key building block.
Bee’s wearable device is always listening — but only stores text transcriptions, not audio. This subtle but important difference positions Bee as a tool for assistive intelligence, rather than surveillance. According to the company, its goal has always been to create an AI companion that “learns with you,” enhancing day-to-day life in a way that feels less intrusive and more useful.
This fits neatly into Amazon’s broader AI strategy. After shuttering its Halo wearables line in 2023, Amazon has refocused on AI-powered services, most recently launching a generative AI-powered upgrade to Alexa, known as Alexa+. Integrating Bee’s capabilities could push Alexa into more context-aware, proactive territory — automatically logging conversations, suggesting follow-ups, or building task lists without users lifting a finger.
The potential is enormous. Real-time conversation capture and transcription can provide a wealth of data, helping to train and refine personalized AI agents. For Amazon, this also represents a possible edge in the race against Google, Meta, Samsung, and others investing heavily in AI-powered smart wearables like earbuds, glasses, and compact assistants.
For investors, this is more than just another big-tech M&A deal — it’s a signal of the next wave in consumer AI. Devices like Bee’s bracelet represent a shift toward always-on, passively intelligent tools that blend into everyday life. And with Amazon in the mix, the scale of adoption could be swift.
There’s also a commercial layer to this: AI wearables could transform e-commerce, advertising, and user engagement. With access to rich, real-world behavioral data, companies could refine product recommendations, automate shopping lists, and deliver marketing that feels like a natural extension of a user’s day — not an interruption.
While privacy concerns will continue to hover over these developments, Amazon says its current user controls will apply to Bee’s device as well. That means opt-in settings, transparency reports, and more granular data handling tools — all of which will be under scrutiny as the tech rolls out.
Ultimately, Amazon’s acquisition of Bee isn’t just about a bracelet — it’s about redefining how AI fits into our daily lives, and who gets to lead the way.
BOCA RATON, Fla.–(BUSINESS WIRE)–Jul. 23, 2025– The ODP Corporation (NASDAQ:ODP) (“ODP,” or the “Company”), a leading provider of products, services, and technology solutions to businesses and consumers, will announce second quarter 2025 financial results before the market open on Wednesday, August 6th, 2025. The ODP Corporation will webcast a call with financial analysts and investors that day at 9:00 am Eastern Time which will be accessible to the media and the general public.
To listen to the conference call via webcast, please visit The ODP Corporation’s Investor Relations website at investor.theodpcorp.com. A replay of the webcast will be available approximately two hours following the event. A copy of the earnings press release, supplemental financial disclosures and presentation will also be available on the website.
About The ODP Corporation The ODP Corporation (NASDAQ:ODP) is a leading provider of products and services through an integrated business-to-business (B2B) distribution platform and omni-channel presence, which includes supply chain and distribution operations, dedicated sales professionals, online presence, and a network of Office Depot and OfficeMax retail stores. Through its operating companies ODP Business Solutions, LLC; Office Depot, LLC; and Veyer, LLC, The ODP Corporation empowers every business, professional, and consumer to achieve more every day. For more information, visit theodpcorp.com.
ODP and ODP Business Solutions are trademarks of ODP Business Solutions, LLC. Office Depot is a trademark of The Office Club, LLC. OfficeMax is a trademark of OMX, Inc. Veyer is a trademark of Veyer, LLC. Grand&Toy is a trademark of Grand & Toy, LLC in Canada. Any other product or company names mentioned herein are the trademarks of their respective owners.